No abstract available.
Calcineurin*

No abstract available.
Calcineurin*

No abstract available.
Calcineurin ; Lichens

No abstract available.
Calcineurin ; Diabetes Mellitus ; Hyperlipidemias

BACKGROUND: Tinea incognito is the dermatophytoses of atypical clinical appearance that is induced by topical and systemic steroid treatment or topical calcineurin inhibitor. OBJECTIVE: The purpose of this study was to investigate the clinical and etiological aspects of tinea incognito. METHODS: In the 10-year-period 2007-2017, we reviewed fifty-one patients with tinea incognito with regards to the age, gender, duration, and associated diseases. The patients with tinea incognito were further evaluated concerning the clinical manifestations and culture of organisms. RESULTS: Age of the tinea incognito was most prevalent in the fifties (23.5%). The male-to-female ratio was 1:1.3. The most common type of infection was tinea corporis (52.9%), followed by tinea faciei (35.3%), tinea manus (5.9%), tinea barbae (3.5%), and tinea cruris (2.0%). The clinical features were to some extent diverse, ranging from eczema-like, seborrheic dermatitis-like, psoriasiform, folliculitis-like, rosacea-like, pyoderma-like, and purpura-like, and discoid lupus erythematosus-like. Trichophyton(T.) rubrum was the most common etiological agent (35.3%), followed by T. mentagrophytes (11.8%), Microsporum(M.) canis (7.8%), T. verrucosum (5.9%), T. erinacei, and M. gypseum (2.0%), respectively. CONCLUSION: Because of the increase in tinea incognito, there is a need for careful mycological examination in patients with tinea incognito.
Calcineurin ; Humans ; Tinea*

Cyclosporine is a calcineurin inhibitor which is used to treat antihistamine-resistant chronic urticaria. Unfortunately, some patients cannot use cyclosporine due to its side effects. Tacrolimus is another calcineurin inhibitor with a slightly different side effect profile from that of cyclosporine, and a few cases of chronic urticaria have been treated with tacrolimus. Here, we report a patient with anti-histamine-resistant chronic urticaria, who could not be treated with cyclosporine, due to side effects, but was controlled successfully with tacrolimus. To the best of our knowledge, this is the first report of tacrolimus-treated chronic urticaria in Korea.
Calcineurin ; Cyclosporine ; Humans ; Korea ; Tacrolimus* ; Urticaria*

BACKGROUND: Lichen striatus is a well-known, acquired, self-healing, linear inflammatory dermatosis. The therapeutic approach that is usually adopted is topical steroid, even though the prolonged use of this may lead to several side-effects, and particularly cutaneous atrophy. OBJECTIVE: The purpose of this study was to evaluate the efficacy of topical calcineurin inhibitors for the treatment of lichen striatus. METHODS: Twenty nine patients received topical application of calcineurin inhibitors twice a day up to the marked disappearance of the cutaneous lesions. RESULTS: Six (20.7%) of 29 patients achieved a complete response after a mean treatment period of 2.5 months. A good response was observed in 8 patients (27.6%) and a partial response was seen in 8 patients (27.6%). Of the 29 patients, 22 patients (75.9%) had more than a 50% response without any severe adverse effects. No significant differences in the therapeutic responses were found with regard to the patients' ages, the duration of the disease and the length of the treatment periods. CONCLUSION: Our results show that topical calcineurin inhibitors may well represent a useful therapeutic alternative for the treatment of lichen striatus.
Calcineurin ; Humans ; Lichens ; Skin Diseases ; Tacrolimus

BACKGROUND: Atopic dermatitis is a chronic, relapsing, inflammatory skin disease, with genetic and environmental background. Successful management of atopic dermatitis requires a multipronged approach. However, standardized guidelines for the management of Korean atopic dermatitis patients do not exist. OBJECTIVE: This study was performed to provide a standardized treatment guideline for atopic dermatitis in Korea. METHODS: On the basis of treatment guidelines proposed by the ADRG (Atopic Dermatitis Research Group), we consider the characteristic provocation factors reported in previous Korean cases and the new modalities which have recently been introduced. RESULTS: Management should compromise of a disease-adapted treatment which combines adjuvant basic therapy, symptomatic relief and, if needed, anti-inflammatory treatment and the identification and avoidance of trigger factors. New therapies such as topical calcineurin inhibitors are also considered to be good alternatives for the long-term control of atopic dermatitis. CONCLUSION: The algorithm contained within the article was presented as the basis for a guideline of clinical practice that could be used to facilitate the treatment of atopic dermatitis at any stage in Korea.
Calcineurin ; Dermatitis ; Dermatitis, Atopic* ; Humans ; Korea ; Skin Diseases

Dermatomyositis (DM) is an idiopathic inflammatory process characterized by proximal muscle weakness and cutaneous lesions, such as the Gottron's sign, heliotrope rash, and erythematous photosensitive rash. Administration of systemic agents for the treatment of underlying systemic diseases leads to remission of the cutaneous lesions in many cases. However, cutaneous lesions may remain refractory to treatment. Pimecrolimus is a calcineurin inhibitor with combined anti-inflammatory and immunomodulatory activity. It has high affinity to the skin and low permeation potential, even in patients with acute skin inflammation and in those undergoing post-topical corticosteroid therapy. We herein report two DM patients whose cutaneous lesions were refractory to conventional treatment but showed dramatic response to topical pimecrolimus. The clinical outcomes suggest that topical pimecrolimus may be a good therapeutic alternative for the management of the cutaneous lesions of DM.
Calcineurin ; Dermatomyositis ; Exanthema ; Humans ; Inflammation ; Muscle Weakness ; Skin ; Tacrolimus

Tacrolimus is a macrolide antibiotic that was isolated from soil microorganism. Its mechanism of action is based on calcineurin inhibition, which results in suppression of antigen-specific T-cell activation and inhibition of inflammatory cytokine release. Four patients with atopic dermatitis participated in this study of the efficacy of topical tacrolimus. Our cases showed significant improvement in the signs and symptoms of atopic dermatitis within a week of starting topical tacrolimus. We report 4 cases of atopic dermatitis treated with 0. 1% tacrolimus ointment.
Calcineurin ; Dermatitis, Atopic* ; Humans ; Soil ; T-Lymphocytes ; Tacrolimus*